The Center for Cancer and Blood Disorders

Bethesda, Maryland 20874

5 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukaemia (AML), Adenoid Cystic Carcinoma, Advanced Melanoma, Advanced Non-small Cell Lung Cancer, Advanced Solid Tumor, Cervical Cancer, Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+), Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+), Colorectal Cancer, EGFR Mutation, Esophageal Cancer, Follicular Lymphoma ( FL)

Studies at this site

• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL — Recruiting now
• A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies — Recruiting now
• First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays — Recruiting now
• Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers — Stopped early
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
• Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma — Stopped early
• Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy — Stopped early
• Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies — Withdrawn before enrolling